These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 24876477)
1. Target small firms for antibiotic innovation. Hwang TJ; Carpenter D; Kesselheim AS Science; 2014 May; 344(6187):967-9. PubMed ID: 24876477 [No Abstract] [Full Text] [Related]
2. Establishing a list of qualifying pathogens under the Food and Drug Administration Safety and Innovation Act. Final rule. Food and Drug Administration, HHS Fed Regist; 2014 Jun; 79(108):32464-81. PubMed ID: 24908687 [TBL] [Abstract][Full Text] [Related]
3. Stat bite: Treatment trials in the PDQ clinical trials database, by phase. J Natl Cancer Inst; 2004 Sep; 96(18):1355. PubMed ID: 15367566 [No Abstract] [Full Text] [Related]
4. Health, Wealth, and the 21st Century Cures Act. Lo AW; Philipson TJ; von Eschenbach AC JAMA Oncol; 2016 Jan; 2(1):17-8. PubMed ID: 26513279 [No Abstract] [Full Text] [Related]
5. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process. Binzak BA Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592 [No Abstract] [Full Text] [Related]
6. Speeding new antibiotics to market: a fake fix? Doshi P BMJ; 2015 Mar; 350():h1453. PubMed ID: 25814536 [No Abstract] [Full Text] [Related]
7. Biomedical policy. U.S. House reveals ambitious biomedical innovation plan. Servick K Science; 2015 Feb; 347(6222):594-5. PubMed ID: 25657222 [No Abstract] [Full Text] [Related]
8. GAIN Act legislation: is it enough? Tillotson GS Lancet Infect Dis; 2012 Nov; 12(11):823-4. PubMed ID: 23099071 [No Abstract] [Full Text] [Related]
10. 2013 FDA drug approvals. Mullard A Nat Rev Drug Discov; 2014 Feb; 13(2):85-9. PubMed ID: 24481294 [No Abstract] [Full Text] [Related]
11. The 21st century cures act: Opportunities and challenges. Sarpatwari A; Kesselheim AS Clin Pharmacol Ther; 2015 Dec; 98(6):575-7. PubMed ID: 26264909 [TBL] [Abstract][Full Text] [Related]
12. Investment in innovation: lessons learned from China. Wiederhold BK Cyberpsychol Behav Soc Netw; 2011 Apr; 14(4):181-2. PubMed ID: 21486173 [No Abstract] [Full Text] [Related]
13. Learning from the 2012-2013 class of breakthrough therapies. Mullard A Nat Rev Drug Discov; 2013 Dec; 12(12):891-3. PubMed ID: 24287765 [No Abstract] [Full Text] [Related]
14. Repairing the broken market for antibiotic innovation. Outterson K; Powers JH; Daniel GW; McClellan MB Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108 [TBL] [Abstract][Full Text] [Related]
16. Regulatory watch: FDA guidance on co-developing investigational drugs. Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094 [No Abstract] [Full Text] [Related]
17. Leveraging Novel and Existing Pathways to Approve New Therapeutics to Treat Serious Drug-Resistant Infections. Hwang TJ; Kesselheim AS Am J Law Med; 2016 May; 42(2-3):429-450. PubMed ID: 29086648 [TBL] [Abstract][Full Text] [Related]
18. Regulatory watch: From big data to smart data: FDA's INFORMED initiative. Khozin S; Kim G; Pazdur R Nat Rev Drug Discov; 2017 May; 16(5):306. PubMed ID: 28232724 [No Abstract] [Full Text] [Related]
19. Oncology's first Phase 0 trial. Rowan K J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322 [No Abstract] [Full Text] [Related]